Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Intercept Pharmaceuticals Inc.

www.interceptpharma.com

Latest From Intercept Pharmaceuticals Inc.

Zydus Cadila Strides Ahead With NASH Filing In India

Cadila has filed for approval of saroglitazar for NASH in India. The drug, which could emerge as the first medicine for the indication if approved, is already being used by a million Indian patients for diabetic dyslipidemia and hypertriglyceridemia.

 

Policy & Regulation Liver & Hepatic

Keeping Track: Oxbryta Approval Headlines Pre-Thanksgiving Week Of News

The latest drug development news and highlights from our US FDA Performance Tracker.

US FDA Performance Tracker Approvals

CymaBay Shelves NASH Drug Seladelpar On Liver Safety Concerns

Atypical histological findings from a Phase IIb NASH study lead CymaBay to terminate mid-stage studies in NASH and PSC and place a Phase III PBC trial on hold.

Clinical Trials Drug Safety

Galectin’s NASH Phase III Trial Will Use Surrogate Measures Of Esophageal Varices

Other NASH registration trails have targeted fibrosis, but Galectin's mostly-resolved discussions with US FDA will allow the belapectin program to focus of signs and symptoms of the disease.

Liver & Hepatic Drug Approval Standards
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Hepatic (Liver)
  • Metabolic Disorders
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Intercept Pharmaceuticals Inc.
  • Senior Management
  • Mark Pruzanski , MD, Pres. & CEO
    Sandip Kapadia, CFO
    David Shapiro, MD, CMO
    Jerome Durso, COO
    Jason Campagna, MD, PhD, CMO
  • Contact Info
  • Intercept Pharmaceuticals Inc.
    Phone: (646) 747-1000
    10 Hudson Yards
    37th Fl.
    New York, NY 10001
    USA
UsernamePublicRestriction

Register